Home › Trials › NCT07677267
Clinical trial Recruiting at 1 site Observational Ages 18 to 115 Men only

Real-world patterns and outcomes for mCRPC patients who have had ARPI, taxane, and 177Lu-PSMA-617

Official title: Real-World Characteristics, Treatment Patterns, and Outcomes Among Adults With mCRPC Previously Treated With an Androgen Receptor Pathway Inhibitor, Taxane-Based Chemotherapy, and Lutetium-177 Vipivotide Tetraxetan

Run by Novartis · NCT07677267 · Data updated 2026-11-12

This real-world study tests how patients with metastatic castration-resistant prostate cancer, who have already received an ARPI, a taxane, and 177Lu-PSMA-617, fare in US practice using PRECISION data.

Quick facts

Study typeObservational
Ages18 Years to 115 Years
SexMen only
Enrollment1067 (estimated)
SponsorNovartis
Industry-sponsored
Locations1 site (East Hanover, New Jersey)
StatusRecruiting
StartedJune 30, 2026
Main results expectedMay 31, 2027
Study endsMay 31, 2027
Registry record updatedOctober 15, 2026
Trial IDNCT07677267 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults (18+) with metastatic castration-resistant prostate cancer who have used an ARPI, a taxane, and 177Lu-PSMA-617, with documented usage from 2021 onward.

Probably not a fit

Patients who have not received all three prior therapies (ARPI, taxane, and 177Lu-PSMA-617) or lack sufficient real-world data may not be expected to benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study analyzes treatment patterns, characteristics, and clinical outcomes of adults with metastatic castration-resistant prostate cancer who have previously received an ARPI, a taxane, and 177Lu-PSMA-617 in the United States. Data are drawn from the PRECISION data platform to reflect real-world practice. The analysis will focus on patients identified on or after January 1, 2021, and will describe how prior therapies relate to subsequent treatments and outcomes.

Why it matters

Potential benefit: If successful, the study could clarify real-world treatment pathways and outcomes for a high-need patient group.

How similar studies have gone: Prior real-world analyses of similar sequences have shown varied outcomes, making this study important to understand current practice.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion criteria:

* Evidence of 177Lu-PSMA-617 use on or after 01 January 2021.
* Evidence of treatment with ≥1 ARPI, before 177Lu-PSMA-617.
* Evidence of treatment with ≥1 taxane, before or after 177Lu-PSMA-617.
* Diagnosis of mCRPC prior to or on the index date. The index date is the date of the last treatment administration of the latest of an ARPI, taxane, and 177Lu-PSMA-617.
* Age ≥18 years at index.

Exclusion criteria:

• None.

Where it's running

  • Novartis
    East Hanover, New Jersey, United States     Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Prostatic Neoplasms, Castration-Resistant 13Novartis 181
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.